Association of hypovitaminosis D with Systemic Lupus Erythematosus and inflammation

Souza, Viviane Angelina de; Bastos, Marcus Gomes; Fernandes, Natália; Mansur, Henrique; Raposo, Nádia Rezende Barbosa; Souza, Daniele Maria Knupp de; Andrade, Luiz Carlos Ferreira de

doi:10.5935/0101-2800.20140062

Cited by 21 publications

(19 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 2 Studies within patients with SLE indicate that lower 25[OH]D levels may correlate with increased disease activity, [3][4][5][6][7][8][9][10][11][12][13][14][15][16] although inconsistently. [17][18][19][20][21][22][23][24] Variation within the vitamin D receptor gene (VDR), the vitamin D receptor protein that binds the active form of vitamin D, 1,25-dihydroxyvitamin D (1,25[OH] 2 D), has been associated with higher SLE disease activity in females 25 and higher damage score. 26 Whether vitamin D is related to risk of developing SLE has not been clearly established.…”

Section: Introductionmentioning

confidence: 99%

Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus

et al. 2016

View full text Add to dashboard Cite

Objective We examined whether measures of vitamin D were associated with transitioning to systemic lupus erythematosus (SLE) in individuals at risk for SLE. Methods 436 individuals who reported having a relative with SLE but who did not have SLE themselves were evaluated at baseline and again an average of 6.3 (± 3.9) years later. Fifty-six individuals transitioned to SLE (≥4 cumulative ACR criteria). 25-hydroxyvitamin D (25[OH]D) levels were measured by ELISA. Six single nucleotide polymorphisms (SNPs) in four vitamin D genes were genotyped. Generalized estimating equations, adjusting for correlation within families, were used to test associations between the vitamin D variables and the outcome of transitioning to SLE. Results Mean baseline 25[OH]D levels (p=0.42) and vitamin D supplementation (p=0.65) were not different between those who did and did not transition to SLE. Vitamin D deficiency (25[OH]D <20 ng/ml) was greater in those who transitioned compared to those who did not transition to SLE (46% versus 33%, p=0.05). The association between 25[OH]D and SLE was modified by CYP24A1 rs4809959, where for each additional minor allele, increased 25[OH]D was associated with decreased SLE risk: 0 minor alleles (adjusted OR:1.03, CI:0.98,1.09), 1 minor allele (adjusted OR:1.01, CI:0.97,1.05), 2 minor alleles (adjusted OR:0.91, CI:0.84,0.98). Similarly, vitamin D deficiency significantly increased the risk of transitioning to SLE in those with two minor alleles at rs4809959 (adjusted OR:4.90, CI: 1.33,18.04). Conclusions Vitamin D status and CYP24A1 may have a combined role in the transition to SLE in individuals at increased genetic risk for SLE.

show abstract

Section: Introductionmentioning

confidence: 99%

Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Moreover, our results agree with the results obtained from studies performed in other countries and across various geographic locations and latitudes. The prevalence of VD insufficiency in SLE patients was 55% in Brazilian [24], 66.7% in Canadian [25], 81.9% in Hungarian [26] and 98.8% in Saudi Arabian SLE patients [27]. In Saudi Arabia 55% of the controls had VD deficiency which can be explained by their traditional clothing that considerably reduces their chance for exposure to sun [27].…”

Section: Discussionmentioning

confidence: 99%

Serum vitamin D in Egyptian patients with systemic lupus erythematous and its association with lupus nephritis

said¹,

Nabih²,

Elewa³

et al. 2018

nt. J. Clin. Rheumatol

View full text Add to dashboard Cite

To assess VD levels in serum of patients with LN in comparison with patients with extra-renal lupus and healthy controls, and to assess the relation between VD levels and the various clinical and laboratory disease parameters. Subjects and Methods: Serum levels of 25(OH)D in 30 SLE without LN (SLE/noLN), 30 SLE with LN (SLE/LN), and 30 matched controls were assessed and estimated for deficiency and insufficiency at 10 and 30 ng/mL, respectively. SLE-related clinical and biochemical data were collected and the disease activity score for all patients was calculated. The association of serum VD with SLE-related features was evaluated Results-VD deficiency and insufficiency are more prevalent in SLE/LN patients (26.7% and 66.7%, respectively) than in SLE/noLN (20% and 63.3% respectively) and then in controls (13.3% and 43.3% respectively) (p=0.013). Serum VD levels were inversely correlated with the SLE-DAI score in SLE/LN patients (p=0.012) and in SLE/noLN (p=0.037). Low serum VD level is significantly associated with fatigue and photosensitivity in SLE/LN patients (p=0.002 and p=0.014 respectively) and in SLE/noLN patients (p=0.021 and p=0.044 respectively). In SLE/LN patients, low VD is associated with proteinuria and anti-dsDNA. Conclusion: VD deficiency and insufficiency are prevalent in patients with SLE and is more prevalent in SLE/LN patients. Low serum VD is significantly correlated with higher disease activity and ESR. Low serum VD is significantly associated with presence of fatigue and photosensitivity. The strongest factors determining the serum VD level among the SLE patients was presence of LN and photosensitivity.

show abstract

“…11 A prospective study showed that vitamin D deficiency was more prevalent in patients with SLE and was associated with higher levels of IL-6 and hematuria, but no correlation with disease activity as assessed by SLEDAI index. 12 On the contrary, data from a single centre registry in Hungary showed negative correlation of SLEDAI score, as well as, anti-double-stranded (ds)DNA autoantibody titres with reduced vitamin D levels in patients with SLE, moreover, they showed that antids-DNA increased from normal to insufficient and further increased from insufficient to deficient patient subsets. 13 A randomaized clinical trial demonstrated that vitamin D 3 supplementation up to 4,000 IU daily was safe and well-tolerated, but failed to diminish the IFN signature in vitamin D-deficient SLE.…”

Section: Introductionmentioning

confidence: 99%

Untitled

2019

MOJWH

View full text Add to dashboard Cite

Introduction:The relationship between serum vitamin D3 (25-OH-Cholecalciferol) and anti-double stranded-DNA (ds-DNA) antibodies in systemic lupus erythematosus (SLE) has been revealed separately; however, a possible link between these two factors and its effect on disease severity in patients with SLE has not been clarified yet. This is the first study investigating the conjoint association of vitamin D3 (VD 3 ) and anti-ds-DNA antibodies on disease activity in Bahraini patients with SLE. Objectives:To evaluate serum VD3 and anti-ds-DNA antibodies as important factors in clinical status in adult Bahraini patients with SLE and to look into the possible correlation between these two factors and their relation to disease activity in this patient's group. Material and methods:Fifty-one Bahraini SLE patients (mean age of 40.8 years, females were 84.3%) followed at Salmanyia Medical Complex in the period between 2016-2018 were included in this retrospective longitudinal (two-time points) study. Only patients who had blood samples that were taken before (baseline) and after oral VD 3 therapy and had anti-ds-DNA antibodies and serum uric acid tested at the same time-point with vitamin D 3 were included. The vitamin D therapy was VD3 tablet 50.000 IU once per week for 3months. Blood samples were obtained at any time between 2-3 months after starting the therapy for determination of serum levels of vitamin D, anti-ds-DNA antibodies, UA, complements (C 3 &C 4 ), but also for calcium, phosphorus, alkaline phosphatase (ALP), parathyroid hormone (PTH), C-reactive protein (CRP) and antinuclear antibodies (ANA). Results:The current study showed that VD therapy bring about two-fold increment in its mean serum level (P<0.0001) with increased serum calcium (P<0.05). Wonderfully, the mean serum levels of ds-DNA auto-antibodies and UA were significantly decreased after VD therapy (p=0.015 and p=0.010, respectively). Interestingly, when the group was segregated by gender and age; the female group and the age group<40 years, independently, showed statistically significant difference in all parameters exactly as the whole group. Conclusion:We evaluated serum levels of anti-ds-DNA antibody and vitamin D as important factors in SLE disease. Our study showed strong inverse correlation between these two factors, thus, the correction of hypovitaminosis D resulted in reduced serum ds-DNA auto antibodies. The current study established the inverse correlation between vitamin D 3 and the disease activity as measured by anti-ds-DNA antibody levels in adult Bahraini patients with SLE. Consequently, we strongly recommend continuous vitamin D 3 supplementation for Bahraini patients with SLE. Citation: Hassan AB, Farid E, Jaradat AA, et al. Correction of hypovitaminosis d lead to reduction of anti-double-stranded DNA antibody levels in Bahraini patients with systemic lupus erythematosus. Citation: Hassan AB, Farid E, Jaradat AA, et al. Correction of hypovitaminosis d lead to reduction of anti-double-stranded DNA antibody levels in Bahraini patients w...

show abstract

Association of hypovitaminosis D with Systemic Lupus Erythematosus and inflammation

Abstract: In our study, vitamin D deficiency was more prevalent in patients with SLE and was associated with higher levels of IL-6 and hematuria.

Cited by 21 publications

References 29 publications

Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus

Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus

Serum vitamin D in Egyptian patients with systemic lupus erythematous and its association with lupus nephritis

Untitled

Contact Info

Product

Resources

About